| Literature DB >> 23028399 |
Patricia Escobar-Páramo1, Claire Gougat-Barbera, Michael E Hochberg.
Abstract
The use of bacteriophages against pathogenic bacteria in health care and in the food industry is now being advocated as an alternative to the use of antibiotics. But what is the evolutionary response for a bacterial population if both antibiotics and phages are used in combination? We employ an experimental evolution approach to address these questions and exposed Pseudomonas fluorescens SBW25 and a related hypermutator strain (mutS-) to the action of the antibiotic rifampicin and the lytic bacteriophage SBW25ϕ2. We then compared the densities, growth rates, and the mutations at the rpoB locus leading to rifampicin resistance of the evolved bacterial populations. We observed that the evolutionary response of populations under different treatments varied depending on the order in which the antimicrobials were added and whether the bacterium was a hypermutator. We found that wild-type rifampicin-resistant populations involved in biofilm formation often reverted to rifampicin sensitivity when stresses were added sequentially. In contrast, when the mortality agents were added simultaneously, phage populations frequently went extinct and the bacteria evolved antibiotic resistance. However, populations of the hypermutator mutS- converged to a single genotype at the rpoB locus. Future investigation on other bacteria and using different antibiotics and bacteriophage are needed to evaluate the generality of our findings.Entities:
Keywords: Pseudomonas; antibiotic resistance; bacteria; experimental evolution; hypermutator; phage therapy
Year: 2012 PMID: 23028399 PMCID: PMC3461141 DOI: 10.1111/j.1752-4571.2012.00248.x
Source DB: PubMed Journal: Evol Appl ISSN: 1752-4571 Impact factor: 5.183
anova for the effects on final bacterial densities of strain type, antimicrobial identity, and the order in which they were added
| Analysis of variance | |||||
|---|---|---|---|---|---|
| Source | DF | Sum of squares | Mean square | ||
| Model | 5 | 212.3108 | 42.4622 | 55.4594 | <0.0001 |
| Error | 138 | 105.6589 | 0.7656 | ||
| Total | 143 | 317.9697 | |||
Figure 1Log10 of bacterial densities (in cfu/mL) of the 12 replicate populations of P. fluorescens SBW25 wild type (WT) and the hypermutator (mutS−), estimated after eight serial transfers under the effects of rifampicin, the lytic bacteriophage SBW25ϕ2, or both. Simultaneous and sequential treatments refer to the temporal sequence in which rifampicin and phage were introduced. In the ‘sequential treatments,’ phages were added after the addition of rifampicin (and the concomitant selection of rif-resistant bacteria). The central line in each diamond is the group mean, the upper and lower lines within the diamonds represent the 95% overlap marks (i.e., how far the diamonds can overlap with the sample means still significantly different), and the upper and lower points of the diamonds represent the 95% confidence limits.
Figure 2Treatment effects on bacterial growth measured as log10 (OD660 24 h/OD660 initial). Data are from 66 selected clones from the different experimental treatments. Diamonds drawn as in Fig. 1 based on transformed data. See main text for methods.
Amino acid substitutions in cluster II of the rpoB gene, responsible for mutational resistance to rifampicin, found in this study. The sequence at the top corresponds to the wild-type ancestral sequence of cluster II (from AA513 to AA579) of the rpoB gene of Pseudomonas fluorescens SBW25, and the amino acids in bold are those substituted in the resistant strains from this study. Note that mutS− populations evolving after the simultaneous addition of rif and phage in KB-rif medium (underlined) converged to a single genotype (D521A). 513 SSQLSQFMDQNNPLSEITHKRRVSALGPGGLTRERAGFEVRDVHPTHYGRVCPIETPEGPNIGLINS579
| WT | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Sensitive ancestors | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS |
| Rifampicin | DL | D | DLHLS | DL | DL | |
| Phage | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS |
| Simultaneous | DLHL | DLHL | ||||
| Rifampicin selection | DLH | DLHL | DL | |||
| With phage in KB | DLH | DLHL | DL | |||
| With phage in KB+rif | DLH | DLHL | DL | |||
| Sensitive ancestors | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS |
| Rifampicin | DLHL | DLHL | D | |||
| Phage | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS | DLHLS |
| Simultaneous | ||||||
| Rifampicin selection | DLH | |||||
| With phage in KB | DLH | |||||
| With phage in KB+rif | DLH | |||||
Figure 3Relative frequencies of strains either resistant (black) or sensitive (dotted) to rifampicin estimated at the end of the experiment by counting bacterial colonies on KB plates containing rifampicin at a concentration of 100 μg/mL.